Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. - Wikidata - awgldk - TriplyDB

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

http://www.wikidata.org/entity/Q34805121

about

Ticagrelor-Associated Conduction Disorder: A Case Report and Review of the Literature.Clopidogrel Response Variability: Review of the Literature and Practical Considerations.Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.Platelet function testing in cardiac surgery.Benefits and risks of P2Y12 inhibitor preloading in patients with acute coronary syndrome and stable angina.Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.Acquired Hemophilia A May Be Associated with Ticagrelor Therapy in a 52-Year-Old Man After a Recent Percutaneous Transluminal Coronary Angioplasty.The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease.Role of P2Y12 Receptor in Thrombosis.Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.GLS-409, an Antagonist of Both P2Y and P2Y, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation

P2860

Q33893920-ED40A8C1-393B-4ADA-B9A1-3672B9209925 Q38640902-F0C4A0D2-E988-4A84-8961-D07428D8AFFD Q38802950-D434E492-1B84-42A4-93F3-E75C79297194 Q38930441-76D0BC1F-FFD7-47DC-943A-1265A69AE4BF Q39449665-DEF0C1F9-1EA5-4D84-9AD6-4FC1AAAC5877 Q40642186-84AAD45A-3574-44C5-92DF-3B77BB8CA0F3 Q41089560-4C82247D-6A97-4623-8CDF-6BFC219DA350 Q41456276-5E4A67C0-0E26-4E18-BB34-4DC0FF0B824B Q51507695-C26F0608-28D5-4C72-B4F7-F368647C5589 Q55444892-57B12F98-B4DF-4892-9FC1-F1A0FD9EFBEA Q59126251-913A2C21-BEC6-40C4-B454-0123AFCA4A66

P2860

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

http://www.wikidata.org/entity/Q34805121

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@ast

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@en

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@nl

type

label

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@ast

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@en

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@nl

prefLabel

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@ast

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@en

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@nl

P1433

Q34805121-29B1B8D6-9840-47A9-A047-E958DD6636A9

P1476

Q34805121-91B0B31A-D32D-46B3-A37D-FAB8311B88C6

P2093

Q34805121-690B03CC-571D-4A14-8863-194763BB80C1

Q34805121-E6E65826-EEFC-4368-BD6C-52F899528C42

P275

Q34805121-E39FDAED-C9BE-415A-98C5-D11ECD925B7B

P2860

Q34805121-03E41E2A-5FB9-4E0A-8C92-62963B912EB1

Q34805121-06D90E89-CB01-4258-8DD4-F43C401C8335

Q34805121-0D8F0248-73E7-4823-836E-89F1A63F35D5

Q34805121-0F5E71BF-26FC-4DF2-8EAF-E3F83E277490

Q34805121-174B23C2-2031-4907-B364-0230C5C37D03

Q34805121-187A9630-0B02-4727-BB7D-098ED297F803

Q34805121-1CAE4587-BDD8-49B7-BBDF-F60BAD836FF4

Q34805121-246D647F-85A1-469F-BEDF-323AD762B2DF

Q34805121-2B62B9BB-6B16-4B62-A317-87765F558E9C

Q34805121-419D042D-974C-49A3-96C7-19432FDE2E16

P304

Q34805121-518B7165-F27D-48E4-8827-BA9BC56830F2

P31

Q34805121-5CD3C47F-242D-4E20-8A8C-B499259C2CEF

Q34805121-FB4B2167-0B49-4398-A7ED-43D84A7711E7

P356

Q34805121-88055E5C-E7C1-46B4-BC98-21BDBA80BC05

P407

Q34805121-B8FC4BF3-9B30-46DE-9B14-93F925D60D8B

P433

Q34805121-B75A4FE2-5EB4-4B6E-87D5-4B0205BF0713

P478

Q34805121-99970C56-66AC-4612-A796-E2723CB7578D

P577

Q34805121-78F95A96-9C17-416D-BE6A-C9604D7FA4BA

Q34805121-852E9E1F-FEB9-4466-B322-6AD1A0A7F411

P5875

Q34805121-8FAB2F63-87C3-4D2A-8EC8-D4E7EAF513B4

P698

Q34805121-3E0FA0E5-0071-4692-8913-5849AA32F6D1

P921

Q34805121-9014EF35-3590-44C1-A94B-776824924AA1

Q34805121-FF2340E1-FFF8-4507-9821-7DF08F1521E4

P932

Q34805121-171F89E4-D53C-4918-AEAE-0AA5C3CDD5E3

P356

P1433

Pharmacotherapy

P1476

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

@en

P2093

Julie H Oestreich

http://www.w3.org/2001/XMLSchema#string

Paul P Dobesh

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

P2860

Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electroca

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.

P304

1077-1090

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1477

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265131219

http://www.w3.org/2001/XMLSchema#string

P698

25164528

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

mechanism of action

P932

4282310

http://www.w3.org/2001/XMLSchema#string